<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843098</url>
  </required_header>
  <id_info>
    <org_study_id>TL-117-202001</org_study_id>
    <nct_id>NCT04843098</nct_id>
  </id_info>
  <brief_title>Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Junde Biotechnology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Junde Biotechnology Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus&#xD;
      paclitaxel in patients with recurrent or metastatic head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2 open label, single arm study, and is divided into three phases: the&#xD;
      single-agent dose-escalation phase Ia trial, the TL117 plus paclitaxel dose-escalation phase&#xD;
      Ib trial, and the open label, multicenter phase 2 trial of TL117 plus paclitaxel.&#xD;
&#xD;
      Adverse events and dose limiting toxicities will be assessed from the first dose of study&#xD;
      drug though day 28. When the maximum tolerated dose (MTD) of TL117 plus paclitaxel is&#xD;
      determined, additional patients will be treated at the defined RP2D dose until occurrence of&#xD;
      unacceptable toxicity, disease progression or withdrawal of consent or death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ia -Dose Limiting Toxicity (DLT) of TL117 treatment</measure>
    <time_frame>From time of the first dosing to time of Cycle 1 Day 28（each cycle is 28 days）</time_frame>
    <description>Per DLT criteria as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib -Dose Limiting Toxicity (DLT) of TL117 plus paclitaxel combination treatment</measure>
    <time_frame>From time of the first dosing to time of Cycle 1 Day 28（each cycle is 28 days）</time_frame>
    <description>Per DLT criteria as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II - Objective response rate (ORR)</measure>
    <time_frame>Every 8 weeks from date of first treatment until date of last treatment up to 12 months</time_frame>
    <description>Objective response rate (ORR): percentage of patients with best overall response of complete response (CR) and partial response (PR) according to RECIST v1.1.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Single arm, open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TL117</intervention_name>
    <description>TL117 capsules orally once daily</description>
    <arm_group_label>Single arm, open label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.</description>
    <arm_group_label>Single arm, open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-70 years old for Phase 1a, 18-75 years old for Phase 1b and 2;&#xD;
&#xD;
          2. Histologically and/or cytologically confirmation of recurrent/metastatic squamous cell&#xD;
             carcinoma of the head and neck;&#xD;
&#xD;
          3. At least one evaluable or measurable tumor lesion;&#xD;
&#xD;
          4. Adequate performance status;&#xD;
&#xD;
          5. A minimum life expectancy of &gt; 3 months;&#xD;
&#xD;
          6. Adequate cardiac, kidney, and liver function;&#xD;
&#xD;
          7. Willingness of all subjects of childbearing potential to use acceptable methods of&#xD;
             birth control;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any chemotherapy, radiotherapy, targeted therapy, immunotherapy, endocrine therapy and&#xD;
             other systematic anti-tumor therapies within 4 weeks prior to the first dose of the&#xD;
             study drug (some exceptions apply)&#xD;
&#xD;
          2. Prior or current PI3K inhibitor therapy;&#xD;
&#xD;
          3. Type 1 or type 2 diabetes requiring antihyperglycemic medication;&#xD;
&#xD;
          4. Major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks&#xD;
             prior to the first dose, or required elective surgery during the study period;&#xD;
&#xD;
          5. Any unresolved toxicities from prior therapy greater than Grade 1;&#xD;
&#xD;
          6. Inability to swallow, or serious gastrointestinal absorption conditions;&#xD;
&#xD;
          7. History of immunodeficiency;&#xD;
&#xD;
          8. Active central nervous system metastases;&#xD;
&#xD;
          9. Active hepatitis B or C virus infection;&#xD;
&#xD;
         10. Uncontrolled active infection;&#xD;
&#xD;
         11. Serious cardiovascular disease；&#xD;
&#xD;
         12. Clinically uncontrollable effusion in the third space;&#xD;
&#xD;
         13. Known allergy and/or contraindications to paclitaxel;&#xD;
&#xD;
         14. Known alcohol or drug dependence;&#xD;
&#xD;
         15. Mental disorders or poor compliance;&#xD;
&#xD;
         16. Pregnant or lactating women;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ye Guo, Dr</last_name>
    <phone>021-38804518</phone>
    <email>pattrickguo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Peng, Dr</last_name>
    <phone>021-38804518</phone>
    <email>pengwei8324@163.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

